Newsletter: UP Chemists Synthesize New Hybrid Molecules That Limit Cancer Cell Spread

[THIS IS A PRESS RELEASE]

By: Eunice Jean C. Patron

Graphical abstract of the study. (Photo credit: Concio et. al., 2025)

According to the International Agency for Research on Cancer (IARC), the Philippines recorded nearly 189,000 new cancer cases and more than 113,000 cancer-related deaths in 2022. Globally, IARC also projects that the number of new cases will rise to over 35 million by 2050, which is a 77% increase from 2022 figures. Meanwhile, the 2025 Philippine National Cancer Summit reports that more than 180,000 new cases are diagnosed each year and cancer is estimated to cause over 300 Filipino deaths daily. These alarming statistics highlight the urgent need for continued research and innovation in cancer treatment.

Newsletter: “Of War and Peace, and Chemistry”: A New Commentary Co-written by One of UP’s Chemistry Experts

[THIS IS A PRESS RELEASE]

By: Eunice Jean C. Patron

While chemistry greatly contributed to the world’s advancement, it also threatens human health and safety. (Photo credit: Michael Glazier, Unsplash)

Dr. Imee Su Martinez of the University of the Philippines – Diliman College of Science’s Institute of Chemistry (UPD-CS IC) and Günter Povoden of the University of Technology’s Institute of Inorganic Chemistry in Vienna, Austria, recently published an article entitled “Of War and Peace, and Chemistry,” which highlights the critical role of chemistry in both enabling warfare and fostering international peace and security.

Newsletter: UP Chemists Modify Anticancer Compound to Improve Safety and Efficacy

[THIS IS A PRESS RELEASE]

Chemical structure of deguelin. (Photo credit: Francisco, J. A., & Paderes, M. C. Inhibitory effects of B-, C-, and E-ring-truncated deguelin derivatives against A549, HCT116, and MCF-7 Cancer Cells. ACS Omega, 8(45): p. 43109–43117)

Scientists from the University of the Philippines – Diliman College of Science (UPD-CS) have transformed the anticancer compound deguelin into a novel class of compounds that show promise as safer and more effective treatments for colon, lung, and breast cancer.